Section Arrow
CASI.NASDAQ
- CASI Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2025/06/01 08:09 EDT
Last
 1.89
+0.01 (+0.53%)
Day High 
1.92 
Prev. Close
1.88 
1-M High
1.9903 
Volume 
4.02K 
Bid
1.87
Ask
1.95
Day Low
1.89 
Open
1.92 
1-M Low
1.635 
Market Cap 
29.13M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.89 
20-SMA 1.89 
50-SMA
52-W High 7.67 
52-W Low 1.635 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.54/-1.63
Enterprise Value
31.66M
Balance Sheet
Book Value Per Share
-0.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
28.54M
Operating Revenue Per Share
2.78
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/01 08:09 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.